Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against...
Month: August 2023
DLH to Participate in Upcoming Sidoti Micro Cap Conference
ATLANTA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan...
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion's Pipeline Recursion's internal pipeline as of Q2 2023Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein...
Tecan schedules conference call on August 15th to discuss half year 2023 financial results
Männedorf, Switzerland, August 8, 2023 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to...
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering...
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and...
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense savings target to $20 to...
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a...
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6...
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half...
Harvard Bioscience Announces Second Quarter 2023 Financial Results
Q2 Revenues of $28.8 millionQ2 GAAP operating income $0.8 million, adjusted operating income $3.6 millionStrong H1 operating cash flow drove...
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost...
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Robust growth and efficient expense execution continuesBOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2...
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
Development Advisory Committee strengthened with the expertise and leadership of Dr. YavariTORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --...